FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology genomics, announced on July 15, 2025, that its Compensation Committee has granted a non-qualified stock option to its new Vice President, Corporate Controller. This grant, part of Personalis' 2020 Inducement Plan, allows the purchase of 100,000 shares of common stock at an exercise price of $6.31 per share, aligning with the closing stock price on the grant date. The option vests over four years, with 25% vesting after one year and the remainder vesting monthly, contingent on continued service. This announcement complies with Nasdaq's Rule 5635(c)(4).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.